Trends in Incidence of Prostate Cancer in Iran and Its 31 Provinces During 2003 - 2016

Author:

Nowroozi Mohammad RezaORCID,Farkhani Ehsan MosaORCID,Hushmandi KiavashORCID,Amini ErfanORCID,Momeni Seyed AliORCID,Inanloo Seyed HassanORCID,Bokaie SaiedORCID,Sharifi LalehORCID

Abstract

Background: Prostate cancer is the most common malignancy in men, which is the second leading cause of cancer-related death. The prevalence of prostate cancer in Iran is lower than in Western and European countries. Objectives: Our study presents an updated incidence rate of prostate cancer in Iran and its provinces, displays its trends, and adds its spatial distribution to the literature. Methods: We investigate the age-standardized incidence rates (ASIRs) per annum of prostate cancer from 2003 to 2016 in Iran, using the data of the cancer registration available by the Ministry of Health and Medical Education. Crude incidence rates were calculated by dividing incident cases by the population of the whole country and each province which was available on the website of Iran Statistic Center. Age standardization was done by the World Health Organization (WHO) standard population and presented according to age and province. Results: The crude number of incident prostate cancer cases in Iran was 49 188 between 2003 and 2016. Age-standardized incidence rate of prostate cancer showed an increasing trend from 4.46 in 2003 to 18.44 per 100 000 in 2016. Mazandaran (29.57 per 100 000 in 2008) and Esfahan (27.5 per 100 000 in 2016 and 26.51 per 100 000 in 2015) were provinces with the highest reported ASIRs, while Sistan and Baluchestan province had the lowest mean of ASIR (1.59 per 100 000) in the period of the study. Conclusions: The incidence of prostate cancer displays an increase of more than 4 times at the end of the study period. However, the increase in coverage of data recording and greater access to diagnostic tests during these years are effective in the reported ASIRS, but the steep slope in the incidence trend of prostate cancer compared to other cancers in Iran shows its capacity to become one of the health problems that underscore the necessity of implementation of control and prevention programs, especially in high-incidence provinces.

Publisher

Briefland

Subject

Pharmacology (medical),Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Surgery

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3